Evidence map›Paper›PMID 41786612›Full record

ArticleModern rheumatology case reports2026

Parallel course of calcinosis and cancer in a patient with anti-NXP2-positive dermatomyositis: A case report.

Christopher A Mecoli, Akila N Viswanathan, Antony Rosen, Livia Casciola-Rosen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Modern rheumatology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christopher A MecoliDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-1429-8392
Akila N ViswanathanDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Antony RosenDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Livia Casciola-RosenDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, Antony Rosen · 2016 to 2026
$8.9M
Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to CancerR01AR073208 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI LIVIA A CASCIOLA-ROSEN, Ami Aalok Shah · 2018 to 2026
$5.2M
Multiparametric Magnetic Resonance Imaging as a Novel Approach to Brachytherapy for Cervical CancerR01CA237005 · NCI · JOHNS HOPKINS UNIVERSITY · PI VISWANATHAN, AKILA · 2020 to 2024
$2.8M
Prediction and Significance of Cancer in Idiopathic Inflammatory MyositisR01AR083912 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Christopher Mecoli · 2024 to 2026
$1.6M
Donald B. and Dorothy L. Stabler FoundationJerome L. Greene FoundationNCI NIH HHS R01 CA237005NIAMS NIH HHS P30 AR070254NIAMS NIH HHS R01 AR073208NIAMS NIH HHS R01 AR083912NIH HHS 1R01AR083912 (to CM)NIH HHS P30-AR070254 (to AR)NIH HHS R01AR073208 (to LCR)NIH HHS R01CA237005 (to AV)
6 · The paper itself

Abstract

backgroundIn patients with dermatomyositis (DM) and anti-nuclear matrix protein 2 autoantibodies, associations with both cancer and calcinosis are well established. However, the relationship between the progression of calcinosis and the development of cancer remains unknown. Herein, we describe a unique case that prompts hypotheses regarding shared immunologic mechanisms underlying these clinical complications. CASE PRESENTATION: We present the case of a 46-year-old woman diagnosed with biopsy-proven anti-nuclear matrix protein 2-positive DM manifesting as proximal muscle weakness, myalgias, pruritic rash, and elevations in creatine phosphokinase. Five years into her disease course, the patient developed an abrupt, coincident severe calcinosis and stage IIB squamous cell carcinoma of the cervix. She required aggressive immunosuppression, immunomodulation, and cancer therapy, which ultimately resulted in the remission of her cancer and improvement of her DM, with her calcinosis achieving a quiescent state. Her case describes a parallel course of calcinosis and cancer, and it highlights the challenges of managing refractory DM with malignancy.

conclusionsOur case demonstrates that calcinosis and cancer can develop concurrently and follow a parallel course over time, suggesting a possible mechanistic link between the two complications. This report also highlights that communication between rheumatology, medical oncology, and radiation oncology is pivotal for optimally treating these complex patients.

Indexed as

CalcinosisCalcinosis CutisCarcinoma, Squamous CellDermatomyositisDNA-Binding ProteinsUterine Cervical NeoplasmsAdenosine TriphosphatasesAutoantibodiesFemaleHumansMiddle AgedAdenosine TriphosphatasesAutoantibodiesDNA-Binding ProteinsMORC3 protein, humananti-NXP2 antibodiesautoantibodiescalcinosisDermatomyositismalignancy

Identifiers

PMID41786612
PMCPMC13002130

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.